KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.96

Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2.

S Stintzing, J Tabernero, T Satoh, A Dasari, S Lonardi, C Eng, R Garcia-Carbonero, E Elez, T Yoshino, A F Sobrero, J C Yao, S Kasper, D Arnold, E Basic, M Granold, M Petschulies, L Wu, Y-C Chung, L Chen, Z Yang, E Van Cutsem

ESMO Open 10(3) 104297

PMID39985889
PMCIDPMC11904580
DOI10.1016/j.esmoop.2025.104297
发表日期2025-02-22
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 1:非 KM 图;Figure 2:森林图/亚组分析图。
摘要

摘要

BACKGROUND: Treatment toxicity and disease-related symptoms of metastatic colorectal cancer (mCRC) can adversely affect quality of life (QoL). Maintaining QoL is an important treatment goal alongside improving survival outcomes. Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) measures the quality of patients' survival by assessing the proportion of survival time that is free of symptoms/toxicity. The phase III FRESCO-2 study met its primary endpoint, demonstrating improved overall survival with fruquintinib plus best supportive care (BSC) versus placebo plus BSC [hazard ratio 0.66, 95% confidence interval (CI) 0.55-0.80, P < 0.001]. This post hoc Q-TWiST analysis compared the benefit-risk of fruquintinib versus placebo in all patients randomized in FRESCO-2. METHODS: Patients with refractory mCRC in the USA, Europe, Japan, and Australia were randomized to receive fruquintinib (n = 461) or placebo (n = 230) plus BSC until disease progression or unacceptable toxicity. Patients' survival time was partitioned as follows: time from randomization with grade 3/4 treatment-emergent adverse events (TEAEs) before progression (TOX); time from randomization to progression without grade 3/4 TEAEs (TWiST); and time from progression to death/censoring (REL). Q-TWiST was calculated as the combined utility-weighted mean durations of each health state, assuming utility coefficients of 1 for TWiST and 0.5 for TOX and REL. RESULTS: Q-TWiST was improved when fruquintinib (versus placebo) was added to BSC, with a between-treatment difference of 2.0 months (95% CI 1.5-2.6 months, P < 0.05) and a relative improvement of 31.4%. This effect was primarily driven by the difference in the TWiST component [mean difference 2.1 months (95% CI 1.8-2.5 months), P < 0.05]. Q-TWiST improvements were consistent in all subgroups, including by age, sex, liver metastases, and primary tumor site. The subgroup and sensitivity analysis results confirmed the robustness of the primary analysis findings. CONCLUSIONS: Fruquintinib provides a clinically meaningful quality-adjusted survival benefit versus placebo in refractory mCRC.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1无图注
非 KM Figure
Figure 1Kaplan–Meier curves for OS, PFS, and toxicity in patients who received (A) fruquintinib plus BSC and (B) placebo plus BSC. BSC, best supportive care; CI, confidence interval; OS, overall survival; PFS, progression-free survival; Q-TWiST, quality-adjusted time without symptoms of disease or toxicity; REL, relapse, defined as time from disease progression to death or censoring; TOX, toxicity, defined as the time spent with grade 3 or 4 treatment-emergent adverse events after randomization and before disease progression; TWiST, time without symptoms of disease or toxicity, defined as time from randomization to disease progression without toxicity.
非 KM Figure
Figure 2Differences in Q-TWiST by subgroup. BSC, best supportive care; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; Q-TWiST, quality-adjusted time without symptoms of disease or toxicity; VEGF, vascular endothelial growth factor; WT, wild type.
非 KM Figure